IP Library Granted Patent US 8,809,314
Granted Patent B1
US 8,809,314 · App. 14/020,230 · Granted Aug 19, 2014

Cephalosporin compound

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,314
App. No.
14/020,230
Granted
Aug 19, 2014
Kind
B1
Abstract

The cephalosporin compound of formula (I) is disclosed, which exhibits antibiotic activity against Gram-negative (e.g., Pseudomonas aeruginosa ) and Gram-positive (e.g., methicillin-resistant Staphylococcus aureus ) bacteria. Methods of manufacturing the compound of formula (I), and uses of the compound in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

Claims (7)

1. The compound of formula (I), or a pharmacologically acceptable salt thereof:

2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , or a pharmacologically acceptable salt thereof.

3. A method of treating a bacterial infection in a host comprising administering to an infected host a pharmaceutical composition comprising an antibacterially effective amount of a compound of claim 1 or a composition of claim 2 .

4. The method of claim 3 , wherein the bacterial infection is caused by a Gram-negative and/or a Gram-positive bacteria.

5. The method of claim 4 , wherein the Gram-negative bacteria is Pseudomonas aeruginosa and the Gram-positive bacteria is Staphylococcus aureus.

6. A method of treating a methicillin-resistant Staphylococcal infection, comprising parenterally administering to a patient in need thereof a pharmaceutical composition comprising a carrier and a therapeutically effective amount of a compound of claim 1 , or a pharmacologically acceptable salt thereof.

7. The method of claim 6 , wherein the therapeutically effective amount is effective against both a Pseudomonas aeruginosa bacteria and a MRSA bacteria with a MIC of not more than about 2 micrograms/mL.

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
NUNC PRO TUNC ASSIGNMENT Recorded Aug 6, 2015
From: CUBIST PHARMACEUTICALS LLC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036268/0626 →
CHANGE OF NAME Recorded Aug 5, 2015
From: CUBIST PHARMACEUTICALS, INC.
To: CUBIST PHARMACEUTICALS LLC
Reel/Frame 036283/0189 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2014
From: HE, YONG; GU, YU GUI; YIN, NING; ZOU, DONG; PEARSON, ANDRE LEE
To: CUBIST PHARMACEUTICALS, INC.
Reel/Frame 032471/0804 →